ArticleTranslational lung cancer research2026
First-line pembrolizumab plus chemotherapy versus bevacizumab plus chemotherapy in response and survival outcomes in PD-L1-negative advanced non-squamous NSCLC: a retrospective comparative cohort study.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Direct real-world comparisons of pembrolizumab plus chemotherapy and bevacizumab plus chemotherapy in programmed cell death ligand 1 (PD-L1)-negative advanced non-squamous non-small cell lung cancer (NSCLC) are limited. We compared response, survival, safety, and blood biomarkers between these regimens. Methods: This single-center retrospective cohort included 160 patients treated at Shanghai Chest Hospital from May 2017 to October 2023: 76 received pembrolizumab plus platinum-pemetrexed chemotherapy and 84 received bevacizumab plus the same chemotherapy backbone. Eligibility required advanced non-squamous NSCLC, PD-L1 tumor proportion score <1%, no actionable driver alteration, Eastern Cooperative Oncology Group performance status 0-1, at least two treatment cycles, and complete data. Laboratory time points were defined as T0 (within 1 week before treatment) and T2 (after two treatment cycles); objective response rate (ORR) and disease control rate (DCR) were assessed after two treatment cycles. Cutoffs were selected using X-tile. Treatment-group Cox models adjusted for age, sex, smoking, stage, metastatic sites, baseline lactate dehydrogenase (LDH), and prognostic nutritional index (PNI); regimen-specific models included variables with univariable P<0.10. Results: The pembrolizumab cohort was older and included more men and patients with lung metastases. At the two-cycle response assessment, ORR (35.5% Conclusions: In this retrospective non-randomized cohort, pembrolizumab plus chemotherapy and bevacizumab plus chemotherapy showed no statistically significant differences in response or PFS, whereas pembrolizumab plus chemotherapy was associated with longer adjusted OS. LDH and PNI provided complementary prognostic information, particularly early on-treatment PNI, supporting further evaluation of these routinely available markers for dynamic risk assessment. Prospective multicenter studies are needed to confirm the treatment association and biomarker thresholds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.